Physician profile
Michaela M Johnson
NPI 1407312549
$9,287.36
in general payments reported to CMS, 2019-2025
36 companies · $1,975 in 2025
The $1,975 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,126 · 2022: $1,671 · 2023: $1,483 · 2024: $2,032 · 2025: $1,975.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,490.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,490.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,304.18 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,020.12 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $963.39 | 2021-2025 | |
| Lilly USA, LLC | $900.41 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $884.63 | 2021-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Novartis Pharmaceuticals Corporation | $419.03 | 2021-2025 | |
| Amgen INC. | $324.36 | 2021-2025 | Repatha, Repatha, Otezla |
| E.R. Squibb & Sons, L.L.C. | $298.17 | 2021-2024 | Eliquis, Camzyos |
| Novo Nordisk INC | $295.47 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $262.36 | 2021-2025 | Trelegy Ellipta |
| Exact Sciences Corporation | $237.95 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $222.17 | 2021-2025 | Verquvo, Belsomra, Capvaxive |
| Astellas Pharma US INC | $209.59 | 2022-2025 | Veozah, Myrbetriq |
| Otsuka America Pharmaceutical, INC. | $192.91 | 2023-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $184.67 | 2021-2022 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michaela Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.